N/A
Completed N=105
Anesthesia and Lymphocytes Apoptosis
Anesthesia
Source: ClinicalTrials.gov NCT01461551 ↗
Enrolled (actual)
105
Serious AEs
0.0%
Results posted
Nov 2014
Primary outcomePrimary: Lymphocyte Count — 0.55; 0.73; 0.73 cells/nanoliter
Summary
Most researches revealed that volatile anesthetic sevoflurane has a more marked cardioprotective effect against ischemia compared with intravenous agent propofol.However, propofol has been suggested to be more benefit for attenuation of surgery-induced immunosuppression.Thus, the aim of this study was to investigate under the specific OPCAB surgical stress, the influence of 3 established anesthetic techniques: sevoflurane, propofol and combine of sevoflurane and propofol maintained anesthesia on the apoptosis of circulating lymphocytes.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Lymphocyte Count |
0.55; 0.73; 0.73 | — |
| SECONDARY Intensive Care Unit Staying Days |
— | — |
Eligibility Criteria
Inclusion Criteria
- male adults
- aged 18-80 yr
- undergoing elective OPCAB surgery containing left anterior descending artery bypass
Exclusion Criteria
- a previous unusual response to any of the experimental anesthetics
- severe cardiac dysrhythmias or ejection fraction below 30%
- hemodynamic instability
- previous surgical coronary artery repair
- anemia, abnormal leukocytes or coagulopathy
- severe hypertension
- severe hepatic (albumin<30g, ascites), renal (serum creatinine greater than 2.0 mg/dl) or pulmonary (preoperative pulmonary function tests moderate-severe) dysfunctions
- concomitant surgical procedures and psychiatric disorders
- Insulin-dependent diabetics
Data sourced from ClinicalTrials.gov (NCT01461551). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.